September 18th 2024
Approval was based on results from the MANDARA Phase III trial, which demonstrated the superiority of Fansenra over Nucala in patients with eosinophilic granulomatosis with polyangiitis.
September 16th 2024
Europe's "Radical" Regulators Drawn Further into Pricing Debate
June 9th 2016Radicals who wield real power at the EMA have gone public with their thinking about the role of regulators in the economic aspects of medicines provision – despite the decades-old EU taboo about linking pricing with authorizations.
Anti-Vaccine Movement Rears Its Ugly Head Again
April 4th 2016Despite research by eminent scientists as to the safety and benefits of immunization for children and adults, the anti-vaccine film "Vaxxed: From Cover-Up to Catastrophe” has all the emotional elements to convince millions that vaccines are unsafe and dangerous, writes Jill Wechsler.